The Neurobiology of ADHD: How the Menstrual Cycle Shapes Symptoms

Author: Associate Professor Caroline Gurvich, Clinical Neuropsychologist, Monash University | Editors: Tashi Stampp and Romina Garcia de leon (blog coordinators) 

Published: October 30th, 2026

Question 1: Is it true that ADHD symptoms can change depending on the stage of the menstrual cycle? If so, what are three key things that women with ADHD should know? 

Yes, ADHD symptoms can significantly change depending on the stage of the menstrual cycle. Our research and research from other groups shows that women with ADHD often experience a worsening of symptoms during the late luteal and perimenstrual phases (the week or two leading up to and during the start of menstruation) when estrogen levels drop and progesterone levels peak and fall.  This can include a heightening of ADHD symptoms, emotional dysregulation and a sense that ADHD medication is less effective.

Three key things women with ADHD should know include:

• Symptoms often peak in the late luteal phase: Executive dysfunction, emotional dysregulation, and attention difficulties tend to intensify during the mid-to-late luteal phase. Women often report increased irritability, chaos, brain fog, fatigue, and decreased focus right before their period.
• Stimulant medication may feel less effective: During the late luteal phase, standard doses of psychostimulant medication may feel less potent or insufficient. Emerging clinical evidence suggests that adjusting or slightly elevating stimulant dosages during the premenstrual week – under clinician supervision – can help stabilise mood, attention, and executive function.
• High co-occurrence with Premenstrual Dysphoric Disorder (PMDD): Women with ADHD have a substantially higher rate of PMDD compared to the general population. Up to 31–45% of women with ADHD meet the criteria for PMDD, which presents as severe premenstrual mood swings, anxiety, depression, and irritability alongside cognitive worsening.

 

Question 2: Can you explain what’s happening in the brain as estrogen and progesterone fluctuate and why might that matter for ADHD symptoms? 

The fluctuation of sex hormones directly impacts key neurotransmitter pathways in the brain that are central to ADHD neurobiology, particularly dopamine and serotonin.

• Estrogen as a Neurotransmitter Enhancer: Estrogen (specifically estradiol) plays an active role in modulating monoamine pathways in the brain. It enhances dopamine transmission, synthesis, and receptor activity, while also modulating serotonin and glutamate pathways. High-estrogen environments – such as the late follicular phase right before ovulation – are thought to boost dopaminergic activity, which generally supports executive function, reward processing, working memory, and cognitive stability.
• Progesterone and Declining Estrogen: During the mid-to-late luteal phase, progesterone peaks and falls and estrogen has a smaller peak and then declines. Progesterone and its metabolite allopregnanolone act on GABA receptors which may reduce the positive dopaminergic enhancement provided by estrogen. As estrogen drops, dopaminergic activity in crucial regions like the prefrontal cortex decreases.

Why it matters for ADHD symptoms: ADHD is characterized by underlying dysregulation in dopamine and noradrenaline pathways. When estrogen drops premenstrually, central dopamine activity drops further. This compound drop weakens the brain’s executive control centre, causing a surge in inattention, brain fog, impulsivity, and emotional dysregulation. Furthermore, because psychostimulants rely on dopamine transmission to function properly, lower estrogen levels can diminish medication efficacy during the premenstrual phase.

 

Question 3: The problem is, many women aren’t diagnosed with ADHD until adulthood. How can receiving a diagnosis help them better understand and manage the ways their symptoms change throughout the menstrual cycle? 

Because adult women are often misdiagnosed with primary mood or anxiety disorders, receiving an accurate ADHD diagnosis provides critical framework shifts:

• Validation and Reduction of Self-Blame: An adult diagnosis helps reframe chronic struggles – such as premenstrual “emotional meltdowns,” brain fog, or paralysis – as biological interactions rather than personal or moral failures.
• Empowerment Through Cycle Tracking: Diagnostic clarity encourages women to track their symptoms across their cycles using specialised logs or apps. Recognising predictable, monthly windows of heightened challenges with executive functioning allows individuals to plan demanding workloads, social commitments, and self-care strategies around high- and low-functioning weeks.
• Targeted Pharmacological Adjustments: Diagnosis enables women and their clinicians to consider tailoring medication regimens specifically to cycle phases – such as implementing temporary premenstrual psychostimulant dose adjustments or combining stimulants with treatments to target co-occurring PMDD.

 

Question 4: How do certain birth control formulations affect ADHD symptoms in women? Is there any evidence of ADHD symptoms lessening if birth control is being taken? 

Research into the direct impact of hormonal contraceptives on ADHD symptoms remains sparse, but initial evidence reveals important considerations:

• Risk of Increased Mood Disturbance with Oral Contraceptives: A large population-based study of young women with ADHD found that using oral hormonal contraceptives – both combined oral contraceptive pills and progestogen-only pills – was associated with a more than fivefold increased risk of developing depression compared to women without ADHD not taking oral contraceptives. Non-oral formulations (such as hormonal IUDs, injections, and implants) carried a more moderate risk increase.
• Hormonal Instability and Adherence Challenges: The hormonal fluctuations associated with pill-free/placebo intervals, combined with synthetic progestogens, can destabilise mood. Additionally, core ADHD traits – such as forgetfulness, poor executive function, and routine inconsistency – can make daily pill compliance difficult, leading to erratic hormone levels that further trigger mood and symptom instability.
• Evidence of Symptom Improvement: Currently, there is no clear clinical evidence demonstrating that standard hormonal birth control reliably lessens core ADHD symptoms. Instead, individual responses vary widely. While some non-oral methods may stabilize systemic hormone levels, oral contraceptives can inadvertently increase depression and emotional distress in vulnerable women with ADHD. Further research in this field is needed.  At this stage, tailored contraceptive counselling and symptom logging are strongly advised.

 

Question 5: If every clinician could understand one thing about ADHD and the menstrual cycle, what would you want it to be, and how might overlooking this connection affect women’s experiences with diagnosis, treatment and care? 

If clinicians could understand one fundamental principle, it is that ADHD symptoms and medication efficacy in women are dynamic, not static – they fluctuate directly in response to sex hormone changes across the menstrual cycle and reproductive life transitions, for example, there is often a worsening of ADHD symptoms in perimenopause.

Consequences of Overlooking This Connection:

• Diagnostic Overshadowing and Misdiagnosis: Clinicians who do not evaluate cyclical patterns often attribute premenstrual symptom surges solely to major depressive disorder, generalized anxiety, or borderline personality traits. Consequently, women are frequently prescribed ineffective psychiatric medications while their underlying ADHD remains unrecognized.
• Inappropriate Treatment Discontinuation: When a patient reports that her stable dose of stimulant medication “stops working” for one week every month, an uninformed clinician might misinterpret this as tolerance, non-adherence, or treatment failure. This can lead to unnecessary medication switches or inappropriate dose increases during phases of the cycle where it isn’t needed.
• Compounded Psychological Harm: Ignoring female-specific biology leaves women navigating monthly cycles of burnout, emotional volatility, and functional impairment without appropriate tools, exacerbating chronic self-blame, low self-esteem, and trauma related to unmanaged neurodivergent struggles.